Cantor Fitzgerald says it's lowering its rating on Obagi Medical Products (OMPI +0.2%) from Buy to Hold on the back of yesterday's merger announcement with Valeant Pharmaceuticals (VRX +0.2%). Cantor says the deal is generally in line with other historical deals in the dermatology space, and after speaking with management it believes the deal has been fully shopped and there aren't likely to be any competing bids.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs